Cargando…

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review

AIMS AND BACKGROUND: A number of population pharmacokinetic (PPK) models of anti-programmed cell death-1 (PD-1) monoclonal antibodies (mAbs) in multiple tumor types have been published to characterize the influencing factors of their pharmacokinetics. This review described PPK models of anti-PD-1 mA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shang, Jingyuan, Huang, Lin, Huang, Jing, Ren, Xiaolei, Liu, Yi, Feng, Yufei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379304/ https://www.ncbi.nlm.nih.gov/pubmed/35983041 http://dx.doi.org/10.3389/fimmu.2022.871372

Ejemplares similares

Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9(+) tumors
por: Santamaria, Silvia, et al.
Publicado: (2022)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
por: Qu, Qiuxia, et al.
Publicado: (2020)

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors
por: Huang, Zhiyu, et al.
Publicado: (2023)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
por: Manso, Taciana, et al.
Publicado: (2023)

P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties
por: Martínez, Darel, et al.
Publicado: (2012)

Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer
por: Chen, Yeshan, et al.
Publicado: (2022)

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
por: Li, Xiuying, et al.
Publicado: (2023)

Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?
por: Santamaria, Silvia, et al.
Publicado: (2017)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Safety and Immunological Evaluation of Interleukin-21 Plus Anti-α4β7 mAb Combination Therapy in Rhesus Macaques
por: Pino, Maria, et al.
Publicado: (2020)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
por: Wei, Joe Q., et al.
Publicado: (2023)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
por: Wines, Bruce D., et al.
Publicado: (2021)

Near‐infrared fluorescence‐labeled anti‐PD‐L1‐mAb for tumor imaging in human colorectal cancer xenografted mice
por: Zhang, Mingyu, et al.
Publicado: (2019)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
por: Golay, Josée, et al.
Publicado: (2020)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
por: Chen, Yezi, et al.
Publicado: (2022)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

Combined IL-2 Immunocomplex and Anti-IL-5 mAb Treatment Expands Foxp3(+) Treg Cells in the Absence of Eosinophilia and Ameliorates Experimental Colitis
por: Abo, Hirohito, et al.
Publicado: (2019)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies
por: Ferrara, Francesca, et al.
Publicado: (2021)

Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-Cancer mAb
por: Kim, Deuk-Su, et al.
Publicado: (2016)

Expression and in vitro function of anti-cancer mAbs in transgenic Arabidopsis thaliana
por: Song, Ilchan, et al.
Publicado: (2020)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Norepinephrine inhibits CD8(+) T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma
por: Geng, Qishun, et al.
Publicado: (2023)

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction
por: Shah, Masaud, et al.
Publicado: (2023)

Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus
por: Gardet, Agnes, et al.
Publicado: (2019)

Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using (2) (1) (2)Pb
por: Boudousq, Vincent, et al.
Publicado: (2013)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fhoi6kh89ppsvk1ni74tr88puj